Study of combination chemotherapy of CPT-11 [irinotecan]/S-1 after anthracycline and taxane in recurrent or metastatic breast cancer (JBCRG-M01).

Trial Profile

Study of combination chemotherapy of CPT-11 [irinotecan]/S-1 after anthracycline and taxane in recurrent or metastatic breast cancer (JBCRG-M01).

Completed
Phase of Trial: Phase I/II

Latest Information Update: 11 Oct 2016

At a glance

  • Drugs Gimeracil/oteracil/tegafur (Primary) ; Irinotecan (Primary)
  • Indications Advanced breast cancer
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 11 Oct 2016 Results presented at the 41st European Society for Medical Oncology Congress
    • 01 Sep 2011 Status changed from recruiting to active, no longer recruiting as reported by University Hospital Medical Information Network - Japan.
    • 08 Jun 2009 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top